I never heard of Seattle Genetics before, but when I searched them on the internet, I found this article about them on BizJournals.Com, which was dated September 14, 2015. It was interesting to read. Seattle Genetics is a biotechnology company focusing on many treatments and therapies, including treatment of cancer.
According to the article, Seattle Genetics CEO Clay Siegall states his company is “busting at the seams” in terms of their large financing rounds and increasing funds in public stock offerings. The company apparently received a huge amount of interest from investors. As a result of their growth, Seattle Genetics lease more office space in the Canyon Park area of Bothell. They will also hire more employees to accommodate their growth.
Mr. Siegall also stated that the proceeds will go to the continuing development of cancer treatment as well as to employees and additional office space.
Clay Siegall serves as President, CEO, and Chairman of Seattle Genetics. He started the company in 1998. Before that, he worked for Bristol-Myers Squibb, the National Cancer Institute, and the National Institutes of Health. He has a history of expertise in the medical field. He is currently focusing on developing antibody-drug conjugates (ADCs) for the treatment of cancer.
Mr. Siegall has written more than 70 publications and holds 15 patents. He holds a Ph.D. in Genetics from George Washington University and a Bachelor of Science in Zoology from the University of Maryland.
What does the future hold for Seattle Genetics? According to Mr. Siegall, all looks good. The company’s continuing growth promises them a bright future.